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fi cient to cause the sustained systemic immunosuppres-
sion that would be responsible for lymphomas  [1] . This 
is true even in young children with moderate-to-severe 
dermatitis affecting a large body surface area  [2] . 
 There is no evidence of photocarcinogenic or muta-
genic potential in animals treated with pimecrolimus. 
Neither pimecrolimus nor tacrolimus have been associ-
ated with an increased risk of malignancies in clinical 
studies  [1] . 
 From clinical use in over 7.5 million patients treated 
with one or the other medication, very few cases of ma-
lignancies have been reported. The number is well below 
the expected background incidence in the population 
treated, even taking into account under-reporting  [1] . 
 Those lymphomas identifi ed by spontaneous adverse-
event reporting systems do not have the clinical presenta-
tion and histology that characterize lymphomas occur-
ring in the setting of immunosuppressive therapy. In con-
trast, lymphomas that have the characteristics of disease 
related to systemic immunosuppression have only been 
 On February 15, 2005, the Pediatric Advisory Com-
mittee of the Food and Drug Administration (FDA) rec-
ommended ‘black box’ warnings for pimecrolimus cream 
(Elidel ® ) and tacrolimus ointment (Protopic ® ) because of 
concerns of potential safety risks (including skin cancer 
and lymphoma). On March 10, 2005, the FDA issued a 
Public Health Advisory informing health-care providers 
of the Agency’s safety concerns associated with use of 
these drugs. We are deeply troubled by the FDA’s actions, 
because there is no evidence that topical use of pimecro-
limus and tacrolimus causes malignancies. 
 Over the last decade, both agents have been extensive-
ly studied in clinical trials involving almost 40,000 pa-
tients, and their effi cacy and safety in the treatment of 
atopic dermatitis have been demonstrated. More than 7.5 
million patients, over half of them children, have been 
treated with these medications since their approval.  
 Systemic absorption of both drugs is very limited and 
even though blood concentrations have been detected in 
some patients, the values are usually very low and insuf-
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observed in animals exposed to high systemic levels of 
calcineurin inhibitors. These animals experienced sys-
temic exposure that is much greater than can be achieved 
with topical application in humans  [1] . 
 There is no increased incidence of systemic infections 
in patients treated with topical calcineurin inhibitors 
 [1] . 
 There is no evidence of systemic immunosuppression 
from topical pimecrolimus or tacrolimus as measured by 
response to vaccination and delayed-type hypersensitiv-
ity  [3–5] . 
 Atopic dermatitis is a chronic, recurring and frustrat-
ing condition. Many patients suffer from atopic dermati-
tis on the face and sensitive skin sites where long-term 
application of topical corticosteroids is not indicated.  
 The health and safety of patients are of paramount 
importance to physicians. We are concerned that the 
aforementioned warnings confuse and unnecessarily wor-
ry patients and their families, as well as health-care pro-
viders. Current labeling suffi ciently describes the appro-
priate use and safety of these medications. We strongly 
believe that the recent recommendations of the Pediatric 
Advisory Committee and the FDA Health Alert are not 
justifi ed based on the scientifi c evidence and should be 
reconsidered. 
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